Development of a Comprehensive Quality-of-Life Measure for Facial and Torso Acne

Abstract

Background

Acne is a chronic skin disorder which generally presents in adolescence but continues into adulthood, and negatively affects both physical and psychosocial well-being. Presently, there are no validated acne-specific quality-of-life (QoL) measures that include dimensions for both facial and torso acne.

Objective:

The objective of this study was to develop a QoL instrument for both facial and torso acne (CompAQ) in accordance with recommended standards.

Methods:

A literature review and Delphi survey of patients and clinicians were used to develop the conceptual framework for outcomes perceived important to acne patients. An initial version of the measure was developed, CompAQ-v1, and pilot tested with patients via cognitive interviews.

Results:

The Delphi survey generated 4 domains (physical, psychological, sociological, and treatment) and 54 items. These, along with a literature review and input from clinical experts, informed the development of the CompAQ-v1. Eleven cognitive interviews were conducted, resulting in the second version of the measure, CompAQ-v2. Psychometric validation resulted in the final 20-item CompAQ measure comprising 5 domains. An abbreviated 5-item measure was also developed (CompAQ-SF).

Conclusion:

CompAQ and CompAQ-SF are instruments intended to evaluate QoL in patients with acne on their face or torso. The former is a 21-item QoL intended for research, while the latter is intended for clinical practice.

Keywords

acne quality of life (QoL)patient-reported outcomes (PRO)CompAQ impacts measure development

Get full access to this article

View all access options for this article.

References

Martin

Lookingbill

Botek

Light

Thiboutot

Girman

CJ.

Health-related quality of life among patients with facial acne—assessment of a new acne-specific questionnaire. Clin Exp Dermatol. 2001;26(5):380-385.

Hay

Johns

Williams

et al . The global burden of skin disease in. 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014;134(6):1527-1534.

Kraning

Odland

GF.

Prevalence, morbidity and cost of dermatologic diseases. J Invest Dermatol. 1979;73:395-401.

Alexis

Daniels

Johnson

Pompilus

Burgess

Harper

JC.

Development of a new patient-reported outcome measure for facial acne: the Acne Symptom and Impact Scale (ASIS). J Drugs Dermatol. 2014;13(3):333-340.

World Health Organization. Constitution of the World Health Organization. In: World Health Organization, ed. Handbook of Basic Documents. 5th ed. Geneva, Switzerland: Palais des Nations; 1952.

Testa

Simonson

DC.

Assessment of quality-of-life outcomes. N Engl J Med. 1996;334(13):835-840.

Schipper

Clinch

Olweny

CLM

. Quality of life studies: definitions and conceptual issues, In: Spilker

ed. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia, PA: Lippincott-Raven; 1996:11-23.

Wolkenstein

Loundou

Barrau

Auquier

Revuz

; Quality of Life Group of the French Society of Dermatology. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol. 2007;56(4):621-623.

Fried

Wechsler

Psychological problems in the acne patient. Dermatol Ther. 2006;19(4):237-240.

10.

Mallon

Newton

Klassen

Stewart-Brown

Ryan

Finlay

AY.

The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol. 1999;140:672-676.

11.

Both

Essink-Bot

Busschbach

Nijsten

Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol. 2007;127(12):2726-2739.

12.

Ware

Jr Sherbourne

. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care. 1992;30:473-483.

13.

Finlay

Khan

Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-216.

14.

Chren

Lasek

Quinn

Mostow

Zyzanski

SJ.

Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1996;107(5):707-713.

15.

Girman

Hartmaier

Thiboutot

Johnson

Barber

DeMuro-Mercon

Waldstreicher

Evaluating health-related quality of life in patients with facial acne: development of a self-administered questionnaire for clinical trials. Qual Life Res. 1996;5(5):481-490.

16.

Salek

Roberts

Finlay

AY.

The practical reality of using a patient reported outcome measure in a routine dermatology clinic. Dermatology. 2007;215(4):315-319.

17.

Hudgens

Harper

Daniels

Banderas

Varon

Alexis

AF.

Validation of a new patient-reported outcome measure for facial acne: the Acne Symptom and Impact Scale (ASIS). J Drugs Dermatol. 2015;14(6):552-559.

18.

Wiebe

Guyatt

Weaver

Matijevic

Sidwell

Comparative responsiveness of generic and specific quality-of-life instruments. J Clin Epidemiol. 2003;56(1):52-60.

19.

Del

RJ.

Study results of benzoyl peroxide 5%/clindamycin 1% topical gel, adapalene 0.1% gel, and use in combination for acne vulgaris. J Drugs Dermatol. 2007;6(6):616-622.

20.

US Food and Drug Administration/Center for Drug Evaluation and Research. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. 2009. http://www.fda.gov/downloads/Drugs/…/Guidances/UCM193282.pdf. Accessed November 15, 2016.

21.

PROMIS. Instrument Development and Validation. Scientific Standards. Version 2.0. 1-72. www.nihpromis.org. Accessed November 2016.

22.

Geist

MR.

Using the Delphi method to engage stakeholders: a comparison of two studies. Eval Program Plan. 2010;33(2):147-154.

23.

Schmitt

Langan

Stamm

Williams

HC.

Core outcome domains for controlled trials and clinical recordkeeping in eczema: international multiperspective delphi consensus process. J Investig Dermatol. 2010;131(3):623-630.

24.

Tan

Wolfe

Weiss

et al . Acne severity grading: determining essential clinical components and features using a Delphi consensus. J Am Acad Dermatol. 2012;67(2):187-189.

25.

Beatty

Willis

GB.

Research synthesis: the practice of cognitive interviewing. Public Opinion Q. 2007;71(2):287-311.

26.

MacCallum

Browne

Sugawara

HM.

Power analysis and determination of sample size for covariance structure modeling. Psychol Methods. 1996;1:130-149.

27.

Nijsten

Dermatology life quality index: time to move forward. J Invest Dermatol. 2012;132(1):11-13.

28.

Nijsten

Meads

McKenna

SP.

Dimensionality of the Dermatology Life Quality Index (DLQI): a commentary. Acta Dermatovenereol. 2006;86(3):289-290.

29.

Dréno

Assessing quality of life in patients with acne vulgaris: implications for treatment. Am J Clin Dermatol. 2006;7(2):99-106.

30.

Tan

Fung

Khan

Condensation and validation of a 4-item index of the Acne-QoL. Qual Life Res. 2006;15(7):1203-1210.

31.

Motley

Finlay

AY.

Practical use of a disability index in the routine management of acne. Clin Exp Dermatol. 1992;17:1-3.

32.

Kellett

Gawkrodger

DJ.

The psychological and emotional impact of acne and the effect of treatment with isotretinoin. Br J Dermatol. 1999;140:273-282.

33.

Hassan

Grogan

Clark-Carter

Richards

Yates

VM.

The individual health burden of acne: appearance-related distress in male and female adolescents and adults with back, chest and facial acne. J Health Psychol. 2009;14(8):1105-1118.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.24 MB